EpizymeInc.
Tafasitamab(Epizyme, Inc.)은 Diffuse Large B-Cell Lymphoma 표적 항체로, Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy 영역에서 개발·상용화 중입니다. 작용기전: checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 90.9% (ClinicalTrials.gov NCT02639910). PK: t½ 13.4 h. 차별점: novel antibody-based therapies, including polatuzumab-containing combinations, loncastuximab tesirine, and tafasitamab plus l.
Diffuse Large B-Cell Lymphoma
Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy
Discontinued
CAR T-Cell Therapy
vedotin, rituximab, cyclophosphamide, doxorubic
humanized anti-CD19 monoclonal antibody, is currently approved, in combination with lenalidomide, for relapse
novel antibody-based therapies, including polatuzumab-containing combinations, loncastuximab tesirine, and tafasitamab plus l
checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab
NK cell–mediated antibody-dependent cellular cytotoxicity
apoptosis, and the TAFA + mVNR combination significantly inhibited, already after 24 h, the phosphorylation of
CD19 CAR T-cell therapy achieved the high
downregulation
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
EpizymeInc.
Tafasitamab(Epizyme, Inc.)은 Diffuse Large B-Cell Lymphoma 표적 항체로, Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy 영역에서 개발·상용화 중입니다. 작용기전: checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 90.9% (ClinicalTrials.gov NCT02639910). PK: t½ 13.4 h. 차별점: novel antibody-based therapies, including polatuzumab-containing combinations, loncastuximab tesirine, and tafasitamab plus l.
Diffuse Large B-Cell Lymphoma
Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy
Discontinued
CAR T-Cell Therapy
vedotin, rituximab, cyclophosphamide, doxorubic
humanized anti-CD19 monoclonal antibody, is currently approved, in combination with lenalidomide, for relapse
novel antibody-based therapies, including polatuzumab-containing combinations, loncastuximab tesirine, and tafasitamab plus l
checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab
NK cell–mediated antibody-dependent cellular cytotoxicity
apoptosis, and the TAFA + mVNR combination significantly inhibited, already after 24 h, the phosphorylation of
CD19 CAR T-cell therapy achieved the high
downregulation
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.